Start of Day Message
LONDON, 17 Apr. 2025 (GLOBE NEWSWIRE) -- This is the Start of Day Message for GlobeNewswire.
GlobeNewswire is operated by Notified and is designated by the FCA as an approved primary information provider.
Disclaimer
The content and accuracy of all information distributed through Notified is wholly the responsibility of the originator. Notified accepts no liability for any losses arising from reliance by any person upon the content of any announcement.
If you have any questions about this message, please Contact Us.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
- Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 202
- Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share